Tedizolid
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Tedizolid
- Tedizolid: From Acute Bacterial Skin and Skin Structure Infections to Orofacial Clefting Syndrome
Tedizolid: From Acute Bacterial Skin and Skin Structure Infections to Orofacial Clefting Syndrome
One-Sentence Summary
Tedizolid is a next-generation oxazolidinone antibiotic used for acute bacterial skin and skin structure infections (ABSSSI), primarily active against Gram-positive pathogens including MRSA. The TxGNN model predicts it may be effective for Orofacial Clefting Syndrome, but this pairing is currently supported by zero clinical trials and zero publications, and the evidence pack itself flags it as a likely false-positive prediction with no known biological plausibility.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute Bacterial Skin and Skin Structure Infections (ABSSSI) (derived from supporting literature in this pack; no EU/Taiwan marketing authorization on file) |
| Predicted New Indication | Orofacial Clefting Syndrome |
| TxGNN Prediction Score | 93.94% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Tedizolid is not available in the structured drug record. However, supporting literature in this evidence pack indicates that Tedizolid is an oxazolidinone-class antibiotic that inhibits bacterial protein synthesis by binding the 23S rRNA of the bacterial ribosome, giving it potent activity against Gram-positive organisms such as MRSA and vancomycin-resistant enterococci. Its approved clinical use is limited to ABSSSI.
Orofacial Clefting Syndrome is a congenital craniofacial developmental disorder with no established relationship to bacterial protein synthesis inhibition. There is no known pharmacological, embryological, or clinical pathway connecting an antibacterial mechanism to craniofacial morphogenesis.
The evidence pack’s own mechanistic assessment for this pairing explicitly concludes that there is no biological plausibility and characterizes it as a typical TxGNN knowledge-graph proximity artifact (i.e., the two nodes are close in embedding space without a real causal or mechanistic link). This prediction should therefore be treated as a low-confidence AI signal rather than a genuine repurposing hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
Tedizolid is currently not marketed in this jurisdiction. No marketing authorizations are on file (total authorizations: 0), so no product-level indication data can be presented.
Safety Considerations
Please refer to the SmPC for safety information. Key warnings, contraindications, and drug-interaction data for Tedizolid are not currently available in this evidence pack (flagged as a Blocking data gap: TFDA label warnings/contraindications must be obtained before any safety pre-assessment can proceed).
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical trial or literature evidence supporting Tedizolid for Orofacial Clefting Syndrome, and the mechanistic rationale itself has been assessed as implausible — a Gram-positive-targeted protein synthesis inhibitor has no known link to craniofacial developmental pathology. This candidate should not advance beyond AI-prediction stage (S0).
To proceed, the following is needed:
- Independent validation of the TxGNN prediction to rule out knowledge-graph ontology/proximity artifacts before any further evaluation
- Detailed mechanism-of-action data (currently a Data Gap)
- TFDA/regulatory label warnings, contraindications, and safety data (Blocking gap — required before any safety pre-assessment)
- If this drug candidate batch is to be pursued further, priority should instead be given to rank 3 (bronchitis), which received a “Research Question” designation based on plausible Gram-positive respiratory coverage, though it likewise currently lacks direct clinical or literature support and would require dedicated evidence collection.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.